Grail's Slump Enters Week 10. Is There Any End in Sight?
Despite a disappointing trial result, there's still a case for buying the stock, with a near-term catalyst on the horizon.
GRAL - GRAIL, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$75.67
DETAILS
HIGH:
$130.00
LOW:
$56.00
MEDIAN:
$65.00
CONSENSUS:
$75.67
UPSIDE:
12.62%
Stock News
GRAIL to Present at the 2026 Jefferies Global Healthcare Conference
MENLO PARK, Calif., May 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3 at 7:35 a.m.
GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead
GRAIL NASDAQ: GRAL said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who identified himself during the discussion as the company's CFO, at a Bank of America event.
GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking
Los Angeles, CA, May 06, 2026 (GLOBE NEWSWIRE) -- For 600 years, the cigar industry has remained stagnant, bound by a tradition that ignored the fundamental laws of thermodynamics. Today, El Septimo Geneva and its Chairman, billionaire engineer Zaya Younan, announce a breakthrough that transcends luxury: the Patented Refrigerated Ashtray.
GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript
GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript
GRAIL Reports First Quarter 2026 Financial Results
Q1 Galleri ® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000 Announced Plans to Integrate the Galleri Test Into Epic Electronic Health Record Platform to Expand Access Nationwide New Data From the NHS-Galleri Trial and PATHFINDER 2 Study to be Presented at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting MENLO PARK, Calif., May 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter of 2026.
GRAIL to Present at the BofA Securities 2026 Health Care Conference
MENLO PARK, Calif., April 30, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12 at 8:40 a.m.
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GRAIL to Announce First Quarter 2026 Financial Results
MENLO PARK, Calif., April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2026 following the close of market on Tuesday, May 5, 2026.
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting
Detailed NHS-Galleri Trial Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation Final PATHFINDER 2 Study Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation More than 174,000 Participants Enrolled Across Both Studies, Demonstrating the Scientific Rigor of Galleri ® Clinical Development Program MENLO PARK, Calif., April 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29-June 2, 2026.
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, April 15, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial missed its primary endpoint. If you lost money on GRAL, submit your information now to discuss your legal rights.
GRAIL, Inc. $GRAL Shares Sold by Carnegie Investment Counsel
Carnegie Investment Counsel lowered its stake in GRAIL, Inc. (NASDAQ: GRAL) by 13.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 213,050 shares of the company's stock after selling 32,265 shares during the period. Carnegie Investment Counsel
Aaron Freidin Sells 45,806 Shares of GRAIL (NASDAQ:GRAL) Stock
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CFO Aaron Freidin sold 45,806 shares of the firm's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the transaction, the chief financial officer owned 260,669 shares in the company, valued at
Joshua Ofman Sells 61,665 Shares of GRAIL (NASDAQ:GRAL) Stock
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) President Joshua Ofman sold 61,665 shares of the firm's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $3,078,316.80. Following the completion of the transaction, the president directly owned 371,216 shares of the company's
Robert Ragusa Sells 123,502 Shares of GRAIL (NASDAQ:GRAL) Stock
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CEO Robert Ragusa sold 123,502 shares of the company's stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $6,165,219.84. Following the sale, the chief executive officer directly owned 518,582 shares in the
GRAIL Partners With Epic to Broaden Galleri Test Access Across US
GRAIL partners with Epic to embed its Galleri cancer test into EHRs, expanding access across nearly 450 health systems and streamlining clinical workflows nationwide.
Grail, Epic Plan Galleri Test Integration For 450 Health Systems
GRAIL, Inc. (NASDAQ: GRAL) shares are up during Wednesday's premarket session.
GRAIL: NHS-Galleri Trial Results Are A Foul Ball, Not A Strikeout
GRAIL: NHS-Galleri Trial Results Are A Foul Ball, Not A Strikeout
GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide
Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within Their Existing Patient Portal Collaboration With Epic Will Allow Clinicians to Seamlessly Order the Galleri Multi-Cancer Early Detection Test at the Point of Care MENLO PARK, Calif., April 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Epic to bring the Galleri® multi-cancer early detection test into one of the nation's most widely used electronic health record (EHR) platforms, supporting broader adoption across health systems in the United States.
Price Targets
Grail price target raised to $56 from $54 at Piper Sandler
$56.00
(was $54.40)
Piper Sandler
Grail price target lowered to $70 from $82 at Baird
$70.00
(was $54.40)
Robert W. Baird
Grail initiated with a Neutral at Mizuho
$58.00
(was $45.76)
Bradley Bowers
·
Mizuho Securities
Grail initiated with a Neutral at Piper Sandler
$54.00
(was $45.76)
Piper Sandler
Grail price target lowered to $60 from $110 at Morgan Stanley
$60.00
(was $43.03)
Kallum Titchmarsh
·
Morgan Stanley
Grail price target lowered to $82 from $113 at Baird
$82.00
(was $101.53)
Catherine Ramsey Schulte
·
Robert W. Baird
Grail price target lowered to $80 from $105 at Canaccord
$80.00
(was $101.53)
Canaccord Genuity
Grail initiated with an Outperform at Baird
$113.00
(was $97.50)
Robert W. Baird
Grail price target raised to $130 from $100 at Guggenheim
$130.00
(was $107.58)
Guggenheim
Grail assumed with an Equal Weight at Morgan Stanley
$110.00
(was $98.27)
Morgan Stanley
Guggenheim Upgrades GRAIL, Inc. (GRAL) to Buy
$100.00
(was $83.39)
Subbu Nambi
·
Guggenheim
Grail price target raised to $85 from $75 at Canaccord
$85.00
(was $78.28)
Kyle Mikson
·
Canaccord Genuity
Grail price target raised to $75 from $43 at Canaccord
$75.00
(was $64.73)
UBS
Canaccord starts Grail with a Buy, sees 'solid upside'
$32.00
(was $26.42)
Canaccord Genuity